Comera SPAC Presentation Deck

Compelling Valuation and Attractive Entry Point Proprietary platform enables potential for significant share. price appreciation. Indicative valuation range can be determined by comparing Comera to related biologics. companies in the market at different stages of development As Comera continues to execute on its business plan, it should have ability to trade similarly to more developed biologics & novel formulation. companies that tend to trade at higher valuations. n Comera LIFE SCIENCES CURRENT ENTERPRISE VALUES OF COMPARABLE PUBLICLY TRADED BIOLOGICS COMPANIES (USD $M) High unmet needs Diversified pipeline Multiple sources of revenue Revenue-generating model Extensive IP protection Strategic collaborations & partnerships Assets under development Near term milestones $151.3¹ I I I I Early-Stage Biosimilar Arecor $110.0 OUTLOOK THERAPEUTICS $306.9 Source: Comera Management, CapitallQ, Company Filings; Market data as of 1/28/22 1. Pro form a diluted enterprise value at $10.00 per share, assumes no redemptions and excludes impact of unvested stock-based compensation and unvested shares pursuant to the new, to-be-established equity incentive plan, earn-out shares and warrants Early-Stage Biobetter EAGLE PHARMACEUTICALS $518.2 Rani THERAPEUTICS :)< $911.5 Comera alvotech LIFE SCIENCES Late-Stage/ Biologics Formulation $2,250.0 Halozyme $4,647.2 30

View entire presentation